Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397837 · ClinicalTrials.gov registry record · Phase 4
Targeting Cognition in Bipolar Disorder With Pramipexole
A Phase 4 study of Bipolar Disorder, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
- 3
- Study locations
NCT02397837 is a Phase 4 study of Bipolar Disorder that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 103 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT02397837, a Phase 4 study of Bipolar Disorder, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
- 3
- Study locations
Study Summary
Converging evidence suggests that patients with bipolar disorder suffer from deficits in neurocognitive functioning that persist, despite remission of acute affective symptoms. These impairments contribute directly to functional disability, highlighting the need for interventions above and beyond standard treatments in order to achieve a full inter-episode recovery. The current study aims to investigate the safety and efficacy of a dopamine agonist (pramipexole), on these persistent cognitive abnormalities in euthymic bipolar patients using a placebo-controlled, adjunctive, 12-week trial design.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pramipexole
Study Locations (3)
New York
- The Zucker Hillside Hospital - Glen Oaks
- Icahn School of Medicine at Mount Sinai - New York
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-07-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02397837
The ClinicalTrials.gov registry entry for NCT02397837 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (69% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02397837 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02397837 about?
NCT02397837 is a clinical study titled "Targeting Cognition in Bipolar Disorder With Pramipexole". Converging evidence suggests that patients with bipolar disorder suffer from deficits in neurocognitive functioning that persist, despite remission of acute affective symptoms. These impairments contribute directly to functional disability, highlighting the need for interventions above and beyond st...
What is the current status of trial NCT02397837?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2014-10. Estimated completion is 2018-07-26.
What conditions does trial NCT02397837 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT02397837?
The interventions under investigation include: Placebo (DRUG), Pramipexole (DRUG).
Who is sponsoring clinical trial NCT02397837?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02397837 being conducted?
This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.